When does Ozempic’s semaglutide patent expire (Orange Book)?
Ozempic (semaglutide) is listed in the FDA’s Orange Book, which records approved drug products and related “patent and exclusivity” information for each product. The Orange Book page identifies specific patents tied to Ozempic and (separately) any periods of regulatory exclusivity that can block generic competition even if a patent runs out.
To find the exact expiration dates that apply to Ozempic, you need to look up the Orange Book listing for “Ozempic” and check the “Patents” section for each listed patent’s “expiration” or “estimated expiration” date, plus the “Exclusivity” section for exclusivity end dates. The Orange Book is the authoritative source for what FDA has linked to Ozempic for patent/exclusivity purposes.
How to check the Orange Book entry for Ozempic quickly
In the Orange Book listing for Ozempic, the key fields to look for are:
- The patent numbers tied to the Ozempic product listing and their expiration dates.
- The “Exclusivity” entries (types like New Chemical Entity/NCE, or other regulatory exclusivities) and their end dates.
- Any “Approvals” or “Drug Product” identifiers tied to the specific Ozempic strength/presentation you care about.
Those values determine whether and when FDA could approve an application for a generic or an “authorized” alternative to enter the market for that specific Ozempic listing.
What if a generic wants approval before patent expiration?
Even if a company files an abbreviated application (or a later-stage application) for a generic, FDA approval timing can still be constrained by Orange Book–listed patents and associated exclusivity. Typically, a generic pathway may require:
- A “paragraph IV” certification against one or more Orange Book patents, or
- Waiting until the relevant patent(s) and/or exclusivity protections have expired.
The Orange Book listing is what drives this certification/eligibility framework, so the specific patent expiration dates matter.
Are there other kinds of exclusivity besides patents that delay generics?
Yes. Patent expiration does not always equal “first generic sale.” The Orange Book includes regulatory exclusivity periods that can extend market protection beyond the last patent expiration date depending on the exclusivity type and the specific Ozempic listing.
This is why you should check both the “Patents” and “Exclusivity” sections on the Orange Book listing.
Where can you find a consolidated patent/exclusivity view for Ozempic?
DrugPatentWatch.com tracks patents and exclusivity information and can be a fast way to cross-check what the Orange Book shows for semaglutide brands. It can help you locate the relevant patent set and see reported expiration timing in one place (though the Orange Book remains the FDA record for official determinations). [1]
Important note: exact dates depend on which Ozempic product listing you mean
Ozempic has multiple strengths and presentations. Orange Book listings can be specific to drug product/dosage form/strength, so patent and exclusivity coverage can differ across entries. The expiration date you see for one listing might not exactly match another Ozempic listing.
If you share which Ozempic strength/presentation you mean (e.g., 0.25 mg, 0.5 mg, 1 mg, 2 mg pen), I can help you pinpoint the exact Orange Book entry to check and interpret what it means for generic timing.
Sources
- DrugPatentWatch.com – Ozempic (semaglutide) patent/exclusivity information